cis-ACPD
Biological Activity
1:1 mixture of (1R,3R)- and (1S,3S)-ACPD. Potent NMDA receptor agonist and selective group II mGluR agonist (EC50 values are 13, 50, >300 and >300 μM at mGluR2, mGluR4, mGluR1 and mGluR5 respectively). Exhibits proconvulsant activity in vivo.
(±)-trans-ACPD and (1S,3R)-ACPD also available.
Technical Data
| M. Wt | 173.17 |
| Formula | C7H11NO4 |
| Storage | Store at RT |
| CAS Number | 477331-06-9 |
| PubChem ID | 16760136 |
| InChI Key | DXLSPTHQGVGVTN-ATXZCBKLSA-N |
| Smiles | [H][C@@]1(CC[C@](N)(C1)C(O)=O)C(O)=O.[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
| Solubility | Soluble to 100 mM in 1eq. NaOH |
Product Datasheets
References
References are publications that support the biological activity of the product.
Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-Δ2-isoxazoline-cyclopentane analogues of glutamic acid. Farmaco 57 889 PMID: 12484537
Schoepp et al (1991) In vitro and in vivo pharmacology of trans- and cis-(±)-1-amino-1,3-cyclopentanedicarboxylic acid: Dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. J.Neurochem. 56 1789 PMID: 1849553
Sunter et al (1991) Actions of the four isomers of 1-aminocyclopentane-1,3-dicarboxylate (ACPD) in the hemisected spinal cord of the neonatal rat. Br.J.Pharmacol. 104 337P
If you know of a relevant reference for cis-ACPD, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: cis-ACPD, cis-ACPD supplier, Potent, NMDA, agonists, group, II, mGluR, Selective, potent, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, mGlur, Group, mGlu2, mGlu3, mGluR2, mGluR3, Metabotropic, (Metabotropic), 0186, Tocris Bioscience
Citations for cis-ACPD
Citations are publications that use Tocris products.
Currently there are no citations for cis-ACPD. Do you know of a great paper that uses cis-ACPD from Tocris? Please let us know.
Reviews for cis-ACPD
There are currently no reviews for this product. Be the first to review cis-ACPD and earn rewards!
Have you used cis-ACPD?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.
